Lambertenghi-Deliliers G, Pogliani E, Maiolo A T, Pacciarini M A, Polli E E
Tumori. 1983 Dec 31;69(6):515-9. doi: 10.1177/030089168306900605.
Twenty-six patients affected by acute leukemia were treated with 4-demethoxydaunorubicin (idarubicin), a new anthracycline compound which in experimental leukemias showed an antitumoral activity superior to daunorubicin (DNR) and doxorubicin (DX), with a higher ratio of active to cardiotoxic doses. A group of 16 patients in relapse received idarubicin at a dosage of 5-6 mg/m2/day for 3 consecutive days; a second group of 6 relapsing and 4 previously untreated cases was treated with a sequential combination of idarubicin and arabinosyl cytosine. In all patients, a significant fall of bone marrow and peripheral blast cells was obtained. These preliminary results suggest that idarubicin has a therapeutic activity against human acute leukemias usually responsive to DNR or DX. The duration of myelosuppression varied from 7 to 50 days, leading in some cases to a high risk of infections. As regards other toxic effects (gastrointestinal, hepatic and acute cardiac toxicity, alopecia), idarubicin appears to be, in our experience, a well-tolerated drug; however, it is too early to comment on delayed cardiac effects.
26例急性白血病患者接受了4-去甲氧柔红霉素（伊达比星）治疗，这是一种新的蒽环类化合物，在实验性白血病中显示出比柔红霉素（DNR）和多柔比星（DX）更强的抗肿瘤活性，且活性剂量与心脏毒性剂量之比更高。一组16例复发患者连续3天接受5 - 6 mg/m²/天剂量的伊达比星治疗；另一组6例复发患者和4例初治患者接受伊达比星与阿糖胞苷的序贯联合治疗。所有患者的骨髓和外周原始细胞均显著减少。这些初步结果表明，伊达比星对通常对DNR或DX有反应的人类急性白血病具有治疗活性。骨髓抑制持续时间为7至50天，在某些情况下导致感染风险较高。至于其他毒性作用（胃肠道、肝脏和急性心脏毒性、脱发），根据我们的经验，伊达比星似乎是一种耐受性良好的药物；然而，对延迟心脏效应进行评论还为时过早。
